Ben Saylor | Authors

Patients With nmCRPC Continue to See Benefit With Darolutamide Despite Comorbidities, Concomitant Medications

February 17, 2022

Data from the ARAMIS trial that were presented at 2022 ASCO GU showed that darolutamide benefit for patients with nonmetastatic castration-resistant prostate cancer was consistent regardless of the number of comorbidities or concomitant medications.